Virbac Posts Strong 2025 Growth Amid Strategic Acquisitions

Event summary

Virbac reported a 7.9% organic revenue growth in 2025, with adjusted EBIT margin at 16.3% despite production shutdowns and higher inventory write-offs.
Consolidated net income increased by 3.2% to €150.5 million, funded by strong cash generation of €93 million.
The company acquired Thyronorm for €107.8 million, expanding its portfolio in feline hyperthyroidism treatment.
2026 guidance projects revenue growth between 5.5% and 7.5%, with adjusted EBIT margin around 17%.
Paul Martingell was appointed CEO effective September 1, 2025.

The big picture

Virbac's strong 2025 performance highlights its strategic agility in the animal health sector, particularly through targeted acquisitions like Thyronorm. The company's ability to navigate regional market dynamics and operational challenges will be critical as it aims to maintain its growth trajectory in a competitive industry.

What we're watching

Integration Challenges: How Virbac will integrate Thyronorm and other recent acquisitions into its existing operations.
Market Dynamics: Whether the company can sustain its growth momentum amid regional market fluctuations, such as in Latin America and Far East Asia.
Operational Efficiency: The pace at which Virbac can address temporary production issues and inventory write-offs to maintain profitability.

Our editorial coverage: